Advertisement

Pituitary

, Volume 11, Issue 3, pp 287–292 | Cite as

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline

  • Giovanna Aparecida Balarini Lima
  • Evelyn de Oliveira Machado
  • Cintia Marques dos Santos Silva
  • Paulo Niemeyer Filho
  • Mônica Roberto Gadelha
Case Report

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.

Keywords

Pituitary apoplexy Cabergoline Macroprolactinoma 

Abbreviations

MRI

Magnetic resonance imaging

CT

Computed tomography

PRL

Prolactin

DA

Dopamine agonist

RNA

Ribonucleic acid

cAMP

Cyclic AMP

References

  1. 1.
    Brougham M, Heusner AP, Adams RD (1950) Acute degenerative changes in adenomas of the pituitary body – with special reference to pituitary apoplexy. J Neurosurg 7:421–439PubMedGoogle Scholar
  2. 2.
    Rovit RL, Fein JM (1972) Pituitary apoplexy: a review and repraisal. J Neurosurg 37:280–288PubMedGoogle Scholar
  3. 3.
    Mohr G, Hardy J (1982) Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 18:181–189PubMedCrossRefGoogle Scholar
  4. 4.
    Rolih CA, Ober KP (1993) Pituitary apoplexy. Endocrinol Metab Clin N Am 22:291–302Google Scholar
  5. 5.
    Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120:118–122CrossRefGoogle Scholar
  6. 6.
    Pinheiro MM, Cukiert A, Salgado LR, Nery M, Goldman J, Pimentel F, Liberman B (1999) Asymptomatic apoplexy in pituitary tumors. Arq Neuro-Psiquiat 57:74–77Google Scholar
  7. 7.
    Tamasawa N, Kurahashi K, Baba T, Hishita R, Murabayashi S, Kashiwamura H, Takebe K (1988) Spontaneous remission of acromegaly after pituitary apoplexy following head trauma. J Endocrinol Invest 11:429–432PubMedGoogle Scholar
  8. 8.
    Reid RL, Quigley ME, Yen SS (1985) Pituitary apoplexy. A review. Arch Neurol 42:712–719PubMedGoogle Scholar
  9. 9.
    Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181–188CrossRefGoogle Scholar
  10. 10.
    Eisberg LA (1977) Pituitary apoplexy. Association of degenerative change in pituitary adenoma with radiotherapy and detection by cerebral computed tomography. Am J Med 63:109–115CrossRefGoogle Scholar
  11. 11.
    Otsuka F, Kageyama J, Ogura T, Makino H (1998) Pituitary apoplexy induced by a combined anterior pituitary test: case report and review of the literature. Endocr J 45:393–398PubMedCrossRefGoogle Scholar
  12. 12.
    Levy A (2003) Hazards of dynamic testing of pituitary function. Clin Endocrinol (Oxf) 58:543–544CrossRefGoogle Scholar
  13. 13.
    Alzetani A, Fisher C, Costa R, Ohri SK (2002) Ptose postcardiac surgery: a case of pituitary apoplexy. Ann Thorac Surg 73:300–301PubMedCrossRefGoogle Scholar
  14. 14.
    Maiza JC, Bennet A, Thom-Kany M, Lagarrigue J, Caron P (2004) Pituitary apoplexy and idiopathic thrombocytopenic purpura: a new case and review of the literature. Pituitary 7:189–192PubMedCrossRefGoogle Scholar
  15. 15.
    Nagarajan DV, Bird D, Papouchado M (2003) Pituitary apoplexy following anticoagulation for acute coronary syndrome. Heart 89:10PubMedCrossRefGoogle Scholar
  16. 16.
    Yamaji T, Ishibashi M, Kosaka K, Fukushima T, Hori T, Manaka S, Sano K (1981) Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol (Copenh) 98:171–177Google Scholar
  17. 17.
    Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumono S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23:395–398PubMedCrossRefGoogle Scholar
  18. 18.
    Alhajje A, Lambert M, Crabbe J (1985) Pituitary apoplexy in an acromegalic patient during bromocriptine therapy. Case report. J Neurosurg 63:288–292PubMedGoogle Scholar
  19. 19.
    Pinto G, Zerah M, Trivin C, Brauner R (1998) Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm Res 50:38–41PubMedCrossRefGoogle Scholar
  20. 20.
    Yang BP, Yang CW, Mindea SA, Tomita T (2005) Pituitary apoplexy. Pediatr Radiol 35:830–831PubMedCrossRefGoogle Scholar
  21. 21.
    Yahagi N, Nishikawa A, Matsui S, Komoda Y, Sai Y, Amakata Y (1992) Pituitary apoplexy following cholecystectomy. Anaesthesia 47:234–236PubMedCrossRefGoogle Scholar
  22. 22.
    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary medical therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705PubMedGoogle Scholar
  23. 23.
    Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin N Am 28:143–169CrossRefGoogle Scholar
  24. 24.
    Bevan JS, Webster J, Christopher WB (1992) Dopamin agonist and pituitary tumor shrinkage. Endocr Rev 13:220–240PubMedCrossRefGoogle Scholar
  25. 25.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet CP, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509PubMedGoogle Scholar
  26. 26.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909PubMedCrossRefGoogle Scholar
  27. 27.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G (1997) Prolactinomas resistant to dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876–883PubMedCrossRefGoogle Scholar
  28. 28.
    Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522PubMedCrossRefGoogle Scholar
  29. 29.
    Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343PubMedCrossRefGoogle Scholar
  30. 30.
    Knoepfelmacher M, Gomes MC, Melo ME, Mendonça BB (2004) Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 7:83–87PubMedCrossRefGoogle Scholar
  31. 31.
    Ebersold MJ, Laws ERJr, Scheithauer BW, Randall RV (1983) Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study. J Neurosurg 58:315–320PubMedGoogle Scholar
  32. 32.
    Arafah BM, Harrington JF, Madhoun ZT, Selman WR (1990) Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 71:323–328PubMedGoogle Scholar
  33. 33.
    Bills DC, Meyer FB, Laws ER Jr, Davis DH, Ebersold MJ, Scheithauer BW, Ilstrup DM, Abboud CF (1993) A retrospective analysis of pituitary apoplexy. Neurosurgery 33:602–608PubMedCrossRefGoogle Scholar
  34. 34.
    Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J (1995) Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab 80:2190–2197PubMedCrossRefGoogle Scholar
  35. 35.
    Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJL (2004) Acute management of pituitary apoplexy – surgery or conservative management? Clin Endocrinol (Oxf) 61:747–752CrossRefGoogle Scholar
  36. 36.
    Wakai S, Fukushima T, Teramoto A, Sano K (1981) Pituitary apoplexy: its incidence and clinical significance. J Neurosurg 55:187–193PubMedGoogle Scholar
  37. 37.
    Cardoso ER, Peterson EW (1984) Pituitary apoplexy: a review. Neurosurgery 14:363–373PubMedCrossRefGoogle Scholar
  38. 38.
    Enjalbert A, Bockaert J (1983) Pharmacological characterization of D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576–584PubMedGoogle Scholar
  39. 39.
    De Camille P, Macconi P, Spada A (1979) Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278:252–254CrossRefGoogle Scholar
  40. 40.
    Brocas H, Van Coevorden A, Seo H, Refetoff S, Vassart G (1981) Dopaminergic control of prolactin mRNA accumulation in the pituitary of the male rat. Mol Cell Endocrinol 22:25–30PubMedCrossRefGoogle Scholar
  41. 41.
    Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294:94–97PubMedCrossRefGoogle Scholar
  42. 42.
    Shull JD, Gorski J (1990) Regulation of prolactin gene transcription in vivo: interactions between estrogen, pimozide, and alpha-ergocryptine. Mol Pharmacol 37:215–221PubMedGoogle Scholar
  43. 43.
    Landolt AM, Minder H, Osterwalder V, Landolt TA (1983) Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 39:625–626PubMedCrossRefGoogle Scholar
  44. 44.
    Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470PubMedCrossRefGoogle Scholar
  45. 45.
    Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozomi T, Mogami H, Matsumoto K (1985) Effects of bromocriptine on prolactin-secreting pituitary adenomas Mechanism of reduction in tumor cell size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Cancer 56:230–238PubMedCrossRefGoogle Scholar
  46. 46.
    Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251PubMedCrossRefGoogle Scholar
  47. 47.
    Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine. A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183PubMedGoogle Scholar
  48. 48.
    Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvarth E, Hoffman JC Jr (1984) Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7PubMedCrossRefGoogle Scholar
  49. 49.
    Kovacs K, Stefaneanu L, Horvath E, Lloyd RV, Lancranjan I, Buchfelder M, Fahlbusch R (1991) Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418:439–446PubMedCrossRefGoogle Scholar
  50. 50.
    Landolt AM, Osterwalder V (1984) Perivascular necrosis in prolactinomas: is it increased by bromocriptine?. J Clin Endocrinol Metab 58:1179–1183PubMedGoogle Scholar
  51. 51.
    Lloyd HM, Meares JD, Jacobi J (1975) Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255:497–498PubMedCrossRefGoogle Scholar
  52. 52.
    Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol 111:46–52PubMedCrossRefGoogle Scholar
  53. 53.
    Yousem DM, Arrington JA, James Zinhreich S, Kumar AJ, Nick Bryan R (1989) Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170:239–243PubMedGoogle Scholar
  54. 54.
    Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C (1992) MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiol 34:43–51CrossRefGoogle Scholar
  55. 55.
    Delgrange E, Gustin T (2005) Cystic macroprolactinoma: primary medical treatment? Intern Med J 35:687–688PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Giovanna Aparecida Balarini Lima
    • 1
  • Evelyn de Oliveira Machado
    • 1
  • Cintia Marques dos Santos Silva
    • 1
  • Paulo Niemeyer Filho
    • 2
  • Mônica Roberto Gadelha
    • 1
    • 3
  1. 1.Division of EndocrinologyClementino Fraga Filho University Hospital/Federal University of Rio de JaneiroRio de JaneiroBrazil
  2. 2.Division of NeurosurgerySanta Casa de Misericórdia do Rio de JaneiroRio de JaneiroBrazil
  3. 3.Rio de JaneiroBrazil

Personalised recommendations